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GeneticsGenetic mutations have been identiﬁed in a modest proportion of patients with combined pituitary hormone
deﬁciency (CPHD). We reported a 3-generation family consisting of 18 members, including 5 affected males
(the proband, his 2 brothers, his cousin, and his maternal uncle; III1–III4, II8) suffered with CPHD. MRI of the
pituitary gland showed hypoplasia of the pituitary gland in affected members. By 19 STR markers and linkage
analysis, we found that the disease gene localized between the DXS987 and DXS1226 markers (LOD
score=2.408, θ=0). All affected male patients inherited the same haplotype from the female carrier (I4).
The proband's mother (II4) and her sister (II3, II6) were obligate female carriers. However, the unaffected
males (II7, II9) in the family did not have this haplotype. These observations conﬁrm a new X-linked recessive
inherited disease in a Chinese family with CPHD and the pathogenic gene is mapped to Xp22.1–Xp11.reau Fund (2010QNA013) and
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Combined pituitary hormone deﬁciency (CPHD) is associated with
deﬁciencies of growth hormone (GH) and at least 1 of the other 5 an-
terior pituitary hormones. Genetic mutations, including mutations in
several autosomal genes (POU1F1, HESX1, PROP1) [1–3], have been
identiﬁed in a modest proportion of patients with CPHD. Over the
past decade, many cases of X-linked recessive familial CPHD have
also been reported. X-linked combined pituitary hormone deﬁciency
has been previously linked to speciﬁc loci. Duplications at locus
Xq22–q27.2 result in panhypopituitarism or mental retardation with
isolated growth hormone deﬁciency [4–6], while duplications at the
locus Xq21.3–q22 (BTK gene) result in hypogammaglobulinemia
with isolated growth hormone deﬁciency.[7] Due to the additional
molecular heterogeneity, the inherited basis of many cases of familial
CPHD remains unclear[8]. Here, we report a new X-linked recessive
inherited disease in a Chinese family with CPHD and the location of
the candidate gene domain.2. Results
The proband (III1), his 2 brothers (III2 and III3), and his cousin
(III4) were all conﬁrmed to have CPHD (hypothyroidism and GH deﬁ-
ciency). The proband's maternal uncle (II8) had GH deﬁciency (GHD).
The subjects had no distinctive facial characteristics and exhibited
normal adrenal function. The MRI scans of the pituitary gland
revealed hypoplasia of the anterior pituitary gland. The pituitary
stalk was thin and difﬁcult to be visualized in subjects III2 and III3
(Fig. 1). The proband (III1) and his brother (III2) exhibited mild men-
tal retardation (IQ of 55 and 68, respectively, Table 1).
The STR markers distributed along the X chromosome were used
for analysis. We noted that the highest LOD scores (2.408 at θ=0)
were obtained for the DXS987 and DXS1226 markers. Four of the
affected male subjects (III1–III4) inherited the same haplotype
(DXS987-G and DXS1226-G) from their maternal grandmother (I4).
The other affected male (II8) inherited this haplotype (DXS987-G
and DXS1226-G) from his mother (I4). However, unaffected males
(II7, II9) in the family did not have this haplotype. Subject II4 and her
sisters (II3, II6) were obligate female carriers; one of their two chromo-
somes contained the affected haplotypes (DXS987-G and DXS1226-G)
(Figs. 2, 3). So the linkage analysis showed that DXS987 and DXS1226
loci had a strong linkage sign, the candidate gene mostly located from
DXS987 (Xp22.1) to DXS1226 (Xp21.3) and conﬁrmed map between
DXS8051 (Xp22.3) and DXS1068 (Xp11).
3. Discussion
In this study, we described the clinical characteristics of an X-
linked form of CPHD (thyroid hormone and growth hormone
SAP
Fig. 1. MRI scan representative of X-linked recessive combined pituitary hormone de-
ﬁciency in subject III3. Sagittal MRI scans of subject III3 showed hypoplasia of the ante-
rior pituitary gland (AP). The pituitary stalk (S) was thin and difﬁcult to visualize due
to its severe attenuation.
Table 1
Summary of clinical data obtained from 5 males affected with X-linked recessive com-
bined pituitary hormone deﬁciency.
Subject Chronological
age (years)
Height
SDS
GH
deﬁciency
Thyroid
hormonea
Gonadal
function
IQ
score
III1 7.4 −5.6 + Low Pre-puberty 55
III2 6 −8.5 + Low Pre-puberty 68
III3 1.5 −4.8 + Low Pre-puberty U
III4 2.5 −6.7 + Low Pre-puberty U
II8 21 −9.1 + Normal Puberty U
U: IQ was not evaluated.
All subjects had GHdeﬁciency and their serumACTH, cortisol, and prolactin concentrations
were normal.
a All subjects had normal serum TSH.
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of 2.408 is of signiﬁcance for an X-linked trait. However, it is not def-
initely signiﬁcant because less than 3.0. Therefore these results are
preliminary. Further families or expansion of this pedigree are re-
quired to conﬁrm this ﬁnding.
CPHD is characterized by deﬁciencies in GH and at least one more
pituitary hormone. The molecular basis of pituitary development is
still not clear. A complex genetic cascade dictates organ commitment,
cell differentiation, and cell proliferation within the anterior pituitary.
Mutations in these genes, including HESX1, LHX3, LHX4, PROP1, and
POU1F1, have been implicated in the etiology of hypopituitarism and
exhibiting autosomal dominant and/or recessive inheritance [8,9]. To
our knowledge, no gene mutations between Xp22.3 and Xp11 had
been reported to be the cause of CPHD or GHD. In the past several de-
cades, many studies of linkage families found that GHD was associated
with X-linked recessive inheritance. Conley ME et al. relied on cytoge-
netics and linkage analyses to study two unrelated families in which af-
fected males presented isolated growth hormone deﬁciency; however,
the immunologic ﬁndings were indistinguishable from those of typical
X-linked agammaglobulinemia (XLA) revealing that the mid-portion
of the long arm of the X chromosome between DXS3 and DXS94 in-
volved the XLA gene and caused the GHD in combination with XLA
[10]. Recently, Stewart et al. reported that the MEF gene (also referred
to as E74-LIKE FACTOR, ELF4, or gene map locus: Xq26) mutation may
be responsible for X-linked hypogammaglobulinemia combined with
isolated GHD [7,11]. The SHOX gene (location: Xp22.33; Yp11.3) be-
longs to the paired homebox family and is located in the pseudoautoso-
mal region 1 (PAR1) of the X and Y chromosomes. Defects in this gene
are associated with idiopathic short stature and Leri–Weill syndrome
[12–14]. Gene SOX3 (location: Xq27.1) encodes a number of transcrip-
tion factors of the SOX family; mutations in this gene have been associ-
ated with X-linked mental retardation with GHD [4,5,15–17]. An
expansion of a polyalanine tract (by 11 alanines) within the transcrip-
tion factor SOX3 (Xq27.1) has been reported in patients with GHD
and variable learning difﬁculties [17]. Over- and under-dosage of
SOX3 as well as gene copy number variation are all associated with hy-
popituitarism or CPHD [18,19].
In our study, the 3-generation family contained fourmales affected
with GHD combined with hypothyroidism (III1, III2, III3, III4), one male(II8) only had GHD, and III1, III2 also showed mild mental retardation.
MRI analyses of their pituitary glands showed hypoplasia of the ante-
rior pituitary gland, and the pituitary stalk was thin and difﬁcult to be
visualized. Preliminary linkage analysis (LOD score=2.408) revealed
that the disease genewasmapped to Xp22.3–Xp11. To our knowledge,
this is the ﬁrst time to ﬁnd CPHD or GHD with recessive X-linkage in a
family associated with genes on Xp22.3–Xp11. The various pheno-
types of this family maybe due to gene mutations on Xp22.3–Xp11
resulting in hypoplasia of the anterior pituitary. The proband (III1)
and his brother (III2) had only mild mental retardation without
other hypothyroidism symptoms and his uncle (II8) only had GHD.
Therefore, we presume it is heterogeneity that affects pituitary cell
secreting growth hormone more than thyroid stimulating hormone
(TSH). Further studies should be carried out on identiﬁcation of the
genes on Xp22.3–Xp11 and its products, which will advance our un-
derstanding of this disabling heritable disease. By advancing the un-
derstanding, treatment or prevention strategies are possible to be
formulated for CPHD associated with these genetic diseases in future.4. Subject and methods
4.1. Clinical studies
The studied 3-generation family is consisted of 18 members, in-
cluding 5 affected males. The pedigree was consistent with an X-
linked recessive condition (Fig. 1). No distinctive facial characteristics
were apparent in the affected males. The pituitary gland was studied
by magnetic resonance imaging (MRI).
Subject III1, i.e., the proband, was diagnosed with secondly hypo-
thyroidism at the age of 7 years and received levothyroxine sodium
as a thyroid hormone substitute. He presented with short stature
with a height of 92 cm and a height standard deviation score (SDS)
of −5.6. His bone age was only 4.8 years. Peak GH levels during
the insulin tolerance and arginine stimulation tests were 0.1 ng/ml
(normalN10 ng/ml), which determined by ELISA. The 2-year growth
rate was 2 cm/year (b3rd percentile). The patient received recombi-
nant human GH (rhGH) as a GH substitute. After 2 years of therapy,
his height reached 112 cm (−2.2 SDS), and his growth rate increased
to 10 cm/year.
Subject III2, the proband's brother, was diagnosed with hypothy-
roidism at 6 years of age. His height was 78 cm (−8.5 SDS), and his
bone age was only 1 year. The growth rate of III2 was 2 cm/year for
2 years. He was treated with levothyroxine sodium, and normal thy-
roid function was restored soon thereafter. This subject underwent 2
different GH provocative tests at the age of 6.5 years, and the ﬁndings
of the 2 tests revealed GHD. After 6 months of rhGH therapy, his
height increased to 84 cm (−7 SDS), and his growth rate increased
to 12 cm/year. When subject III3, the proband's second brother, was
diagnosed with hypothyroidism at 1.5 years of age, the family under-
went medical investigation. Subject III3 presented with a height of
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Fig. 3. Linkage analysis: parametric analysis, model: recessive_model. The highest LOD scores, 2.408 at θ=0, were obtained for the DXS987 and DXS1226 markers. LOD scores of
DXS8051 and DXS1068 were−13.592 and−1.848. So DXS987 and DXS1226 loci had a strong linkage sign, the candidate gene mostly located from Xp22.1 to Xp21.3 and conﬁrmed
map from DXS8051 (Xp22.3) to DXS1068 (Xp11).
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mal thyroid function, GHDwas conﬁrmed at the age of 2 years. Subject
III4, the proband's cousin, was diagnosed with hypothyroidism and
GHD at 2.5 years of age. His height was 68 cm (−6.7 SDS). In the
familial medical investigation, subject II8, the proband's maternal
uncle, was diagnosed with GHD without hypothyroidism at 21 years
of age. His presenting height was 114.5 cm (−9.1 SDS) and bone age
13 years, and he exhibited G2 stage sex development. Subjects III1
and III2 were evaluated for verbal and performance intelligence
quotient (IQ) and for socioadaptive behavior by the Wechsler Intelli-
gence Scale for Children—Revised (WISC-R). The serumACTH, cortisol,
and prolactin concentrations were normal in the 5 affected males.
Written informed consent was obtained from each participant.
The study was approved by the Ethics Committee of the Children's
Hospital of Zhejiang University School of Medicine.
4.2. Linkage study
Genomic DNA was extracted from the venous blood collected from
the 18 family members (I1–I4, II1–II9, III1–III5). We performed analyses
with a total of 19 short tandem repeat (STR) markers distributed over
the entire X chromosome, including DXS1060, DXS8051, DXS987,
DXS1226, DXS1214, DXS1068, DXS993, DXS991, DXS986, DXS990,
DXS1106, DXS1001, DXS1047, DXS1062, DXS1211, DXS984, DXS1205,Fig. 2. (A) Pedigree of the family with combined pituitary hormone deﬁciency located in Xp
were constructed by using STR markers distributed over the entire X chromosome. The haplo
are shown as G. (B) The proband's family. III1, III2, III3 were diagnosed with GHD and hypo
stature.DXS8091, and DXS1073 (Table 2). Blood samples were assayed for STR
markers and divided into 4 panels. Primers with a 5′ FAM ﬂuorescent
label were designed online by using Primer3 software (http://frodo.wi.
mit.edu/cgi-bin/primer3). Polymerase chain reaction of the ﬂuorescent
ampliﬁed length polymorphismwas performed according to the follow-
ing protocol. Each panel contains a 20-μl reaction mixture, including
1×HotStarTaq buffer, 3 mMMg2+, 0.3 mM dNTP 1 U HotStarTaq poly-
merase (Qiagen Inc.), 1 μl of template DNA and a mixture of primers
(the primers of the STR markers see in supplementary material): Panel
1: 0.1 μM DXS1001F/R, 0.1 μM DXS1205F/R, 0.1 μM DXS990F/R, 0.1 μM
DXS1073F/R, 0.25 μM of DXS1106F/R; Panel 2: 0.1 μM DXS1211F/R,
0.1 μM DXS1047F/R, 0.1 μM DXS1068F/R, 0.1 μM DXS1062F/R, 0.1 μM
DXS993F/R, 0.1 μM DXS8091F/R; Panel 3: 0.1 μM DXS991F/R, 0.1 μM
DXS1060F/R, 0.1 μM DXS984F/R, 0.3 μM DXS8051F/R; Panel 4: 0.1 μM
of DXS1226F/R, 0.1 μM DXS986F/R, 0.1 μM DXS1214F/R, 0.25 μM of
DXS987F/R. The cycling program was 95 °C for 15 min; 11 cycles of
94 °C for 20 s, 62 °C per cycle for 40 s with a reduction of 0.5 °C after
each cycle, and 68 °C for 2 min; 24 cycles of 20 s at 94 °C, 40 s at 56 °C,
and 2 min at 68 °C; and ﬁnal elongation for 1 h at 60 °C. PCR products
were diluted 1:20 and then genotyped with an ABI3130xl Genetic Ana-
lyzer. Two-point linkage and haplotypes of the X chromosome and STR
markers were calculated using the MLINK computer program (http://
www.sph.umich.edu/csg/abecasis/Merlin/index.html). Analyses were
performed under the assumption that disease allele frequency was22.3–Xp11. Affected individuals display GH deﬁciency and hypothyroidism. Haplotypes
type segregation is indicated by A, C, D, E, G, H, I, and K. Markers mapping to the region
thyroidism; no distinctive or apparent characteristics were observed except for short
Table 2
STR information.
STR no. Gene position Genetic D
DECODE
Genetic
Marshﬁeld
Repeat unit Panel
DXS1060 Xp22.3 12.71 15.12 (tg)25 3
DXS8051 Xp22.3 – 17.29 (gt)24 3
DXS987 Xp22.1–p21.3 28.2 22.18 (tg)27 4
DXS1226 Xp22 38.7 27.59 (gt)27 4
DXS1214 Xp21.2 46.21 33.54 (tg)17 4
DXS1068 Xp11 60.25 37.33 (ca)19 2
DXS993 Xp11.4 – 42.21 (ac)19 2
DXS991 Xp11.21 79.2 52.5 (ac)23 3
DXS986 Xq21.1 86.84 57.37 (tg)15+(ta)14 4
DXS990 Xq21.32 94.92 60.62 (tg)19 1
DXS1106 Xq22 – 66.58 (ca)20 1
DXS1001 Xq24 120.35 75.79 (ca)22 1
DXS1047 Xq26–q27 – 82.07 (ctat)12+(tg)20 2
DXS1062 Xq24–qter 141.15 82.84 (tg)20 2
DXS1211 Xq26.2 142.03 83.92 (ac)17 2
DXS984 Xq26.3 145.8 85.55 (ac)19 3
DXS1205 Xq23–q27 147.46 87.56 (ac)17 1
DXS8091 Xq28 167.3 96.14 (ca)18 2
DXS1073 Xq27 188.22 102.35 (tg)20 1
444 C.L. Wang et al. / Genomics 98 (2011) 440–4440.00001 and the model of inheritance was X-linked recessive with a
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